MX2014011921A - Nuevos derivados de tienopirimidina, procesos para su preparacion y sus usos terapeuticos. - Google Patents

Nuevos derivados de tienopirimidina, procesos para su preparacion y sus usos terapeuticos.

Info

Publication number
MX2014011921A
MX2014011921A MX2014011921A MX2014011921A MX2014011921A MX 2014011921 A MX2014011921 A MX 2014011921A MX 2014011921 A MX2014011921 A MX 2014011921A MX 2014011921 A MX2014011921 A MX 2014011921A MX 2014011921 A MX2014011921 A MX 2014011921A
Authority
MX
Mexico
Prior art keywords
preparation
processes
therapeutic uses
thienopyrimidine derivatives
novel thienopyrimidine
Prior art date
Application number
MX2014011921A
Other languages
English (en)
Other versions
MX355104B (es
Inventor
Olivier Duclos
Sergio Mallart
Jean-Christophe Carry
Fabienne Chatreaux
Stéphanie Deprets
Vincent Leroy
Dominique Melon-Manguer
Maria Mendez-Perez
Fabrice Vergne
Original Assignee
Sanofi Sa
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Family has litigation
First worldwide family litigation filed litigation Critical https://patents.darts-ip.com/?family=48095815&utm_source=***_patent&utm_medium=platform_link&utm_campaign=public_patent_search&patent=MX2014011921(A) "Global patent litigation dataset” by Darts-ip is licensed under a Creative Commons Attribution 4.0 International License.
Application filed by Sanofi Sa filed Critical Sanofi Sa
Publication of MX2014011921A publication Critical patent/MX2014011921A/es
Publication of MX355104B publication Critical patent/MX355104B/es

Links

Classifications

    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00Medicinal preparations containing organic active ingredients
    • A61K31/33Heterocyclic compounds
    • A61K31/395Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/55Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having seven-membered rings, e.g. azelastine, pentylenetetrazole
    • A61K31/553Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having seven-membered rings, e.g. azelastine, pentylenetetrazole having at least one nitrogen and one oxygen as ring hetero atoms, e.g. loxapine, staurosporine
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00Medicinal preparations containing organic active ingredients
    • A61K31/33Heterocyclic compounds
    • A61K31/395Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/495Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
    • A61K31/505Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim
    • A61K31/519Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim ortho- or peri-condensed with heterocyclic rings
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00Medicinal preparations containing organic active ingredients
    • A61K31/33Heterocyclic compounds
    • A61K31/395Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/55Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having seven-membered rings, e.g. azelastine, pentylenetetrazole
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00Medicinal preparations containing organic active ingredients
    • A61K31/33Heterocyclic compounds
    • A61K31/395Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/55Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having seven-membered rings, e.g. azelastine, pentylenetetrazole
    • A61K31/551Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having seven-membered rings, e.g. azelastine, pentylenetetrazole having two nitrogen atoms, e.g. dilazep
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00Antineoplastic agents
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • CCHEMISTRY; METALLURGY
    • C07ORGANIC CHEMISTRY
    • C07DHETEROCYCLIC COMPOUNDS
    • C07D495/00Heterocyclic compounds containing in the condensed system at least one hetero ring having sulfur atoms as the only ring hetero atoms
    • C07D495/02Heterocyclic compounds containing in the condensed system at least one hetero ring having sulfur atoms as the only ring hetero atoms in which the condensed system contains two hetero rings
    • C07D495/04Ortho-condensed systems
    • CCHEMISTRY; METALLURGY
    • C07ORGANIC CHEMISTRY
    • C07DHETEROCYCLIC COMPOUNDS
    • C07D519/00Heterocyclic compounds containing more than one system of two or more relevant hetero rings condensed among themselves or condensed with a common carbocyclic ring system not provided for in groups C07D453/00 or C07D455/00

Abstract

La presente invención se refiere a compuestos de fórmula (I): (ver Fórmula) en la que R6 es -CONH2 o un grupo -C(Ra)(Rß)(OH); R es un grupo fenilo o heteroarilo sustituido; R7 es un grupo arilo o heteroarilo opcionalmente sustituido. Procesos para su preparación y su uso terapéutico.
MX2014011921A 2012-04-03 2013-04-02 Nuevos derivados de tienopirimidina, procesos para su preparacion y sus usos terapeuticos. MX355104B (es)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
FR1253044A FR2988722B1 (fr) 2012-04-03 2012-04-03 Nouveaux derives de thienopyrimidines, leurs procedes de preparation et leurs utilisations therapeutiques
PCT/EP2013/056958 WO2013150036A1 (en) 2012-04-03 2013-04-02 Novel thienopyrimidine derivatives, processes for the preparation thereof and therapeutic uses thereof

Publications (2)

Publication Number Publication Date
MX2014011921A true MX2014011921A (es) 2015-02-24
MX355104B MX355104B (es) 2018-04-05

Family

ID=48095815

Family Applications (1)

Application Number Title Priority Date Filing Date
MX2014011921A MX355104B (es) 2012-04-03 2013-04-02 Nuevos derivados de tienopirimidina, procesos para su preparacion y sus usos terapeuticos.

Country Status (38)

Country Link
US (6) US9115140B2 (es)
EP (1) EP2834248B1 (es)
JP (1) JP6096278B2 (es)
KR (1) KR102039764B1 (es)
CN (2) CN107652303B (es)
AR (1) AR090572A1 (es)
AU (1) AU2013244992B2 (es)
BR (1) BR112014024489B1 (es)
CA (1) CA2868685C (es)
CL (1) CL2014002661A1 (es)
CO (1) CO7091179A2 (es)
CR (1) CR20140435A (es)
CY (1) CY1117843T1 (es)
DK (1) DK2834248T3 (es)
DO (1) DOP2014000216A (es)
EA (1) EA025558B1 (es)
ES (1) ES2577382T3 (es)
FR (1) FR2988722B1 (es)
HK (2) HK1201263A1 (es)
HR (1) HRP20160649T1 (es)
HU (1) HUE027895T2 (es)
IL (1) IL234960A (es)
MA (1) MA37384B1 (es)
MX (1) MX355104B (es)
MY (1) MY166151A (es)
PE (1) PE20150289A1 (es)
PH (1) PH12014502180A1 (es)
PL (1) PL2834248T3 (es)
PT (1) PT2834248E (es)
RS (1) RS54850B1 (es)
SG (1) SG11201406091RA (es)
SI (1) SI2834248T1 (es)
TN (1) TN2014000415A1 (es)
TW (1) TWI579288B (es)
UA (1) UA112685C2 (es)
UY (1) UY34725A (es)
WO (1) WO2013150036A1 (es)
ZA (1) ZA201407021B (es)

Families Citing this family (13)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
FR2988722B1 (fr) 2012-04-03 2014-05-09 Sanofi Sa Nouveaux derives de thienopyrimidines, leurs procedes de preparation et leurs utilisations therapeutiques
CN110372720B (zh) * 2014-05-28 2021-03-05 锦州奥鸿药业有限责任公司 一类激酶抑制剂
CN111440189B (zh) * 2015-04-24 2022-08-09 广州再极医药科技有限公司 稠环嘧啶氨基衍生物、其制备方法、中间体、药物组合物及应用
CN113549069A (zh) * 2015-12-27 2021-10-26 重庆复创医药研究有限公司 一类激酶抑制剂
MX2018013573A (es) * 2016-05-07 2019-08-01 Shanghai Fochon Pharmaceutical Co Ltd Ciertos inhibidores de la proteína cinasa.
UA126589C2 (uk) 2017-09-14 2022-11-02 Даїті Санкіо Компані, Лімітед Сполука, яка має циклічну структуру
ES2910071T3 (es) 2018-03-08 2022-05-11 Incyte Corp Compuestos de aminopirazina diol como inhibidores de PI3K-Y
CN110551142B (zh) * 2018-05-31 2023-05-12 上海再极医药科技有限公司 一种稠环嘧啶类化合物的盐、晶型及其制备方法和应用
WO2020010003A1 (en) 2018-07-02 2020-01-09 Incyte Corporation AMINOPYRAZINE DERIVATIVES AS PI3K-γ INHIBITORS
US11034669B2 (en) 2018-11-30 2021-06-15 Nuvation Bio Inc. Pyrrole and pyrazole compounds and methods of use thereof
CN110922421B (zh) * 2019-12-17 2023-05-05 安徽英特美科技有限公司 一种n-甲基-1,2,5,6-四氢吡啶-4-硼酸频哪醇酯的合成方法
WO2021180032A1 (en) * 2020-03-13 2021-09-16 Guangzhou Maxinovel Pharmaceuticals Co., Ltd. Novel Therapeutic Methods
CN116731035A (zh) * 2022-03-08 2023-09-12 广州再极医药科技有限公司 一种噻吩并嘧啶类化合物、中间体、其制备方法、组合物和应用

Family Cites Families (13)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
DE1470356A1 (de) * 1964-01-15 1970-04-30 Thomae Gmbh Dr K Neue Thieno[3,2-d]pyrimidine und Verfahren zu ihrer Herstellung
CN1280580A (zh) * 1997-11-11 2001-01-17 辉瑞产品公司 用作抗癌药的噻吩并嘧啶和噻吩并吡啶衍生物
EP1181296A1 (en) 1999-06-03 2002-02-27 Abbott Laboratories Cell adhesion-inhibiting antiinflammatory compounds
DE10042997A1 (de) 2000-09-01 2002-03-14 Merck Patent Gmbh Thienopyrimidine
US20080108611A1 (en) 2006-01-19 2008-05-08 Battista Kathleen A Substituted thienopyrimidine kinase inhibitors
KR101402474B1 (ko) * 2006-04-26 2014-06-19 제넨테크, 인크. 포스포이노시티드 3-키나제 억제제 화합물 및 이를 포함하는 약학적 조성물
AU2007333394C1 (en) 2006-12-08 2011-08-18 Novartis Ag Compounds and compositions as protein kinase inhibitors
EP3109249A1 (en) * 2007-11-15 2016-12-28 YM BioSciences Australia Pty Ltd N-containing heterocyclic compounds
DE102008017853A1 (de) * 2008-04-09 2009-10-15 Merck Patent Gmbh Thienopyrimidine
KR101147550B1 (ko) * 2009-10-22 2012-05-17 한국과학기술연구원 단백질 키나아제 저해활성을 가지는 2,7-치환된 티에노[3,2-d]피리미딘 화합물
KR101094446B1 (ko) * 2009-11-19 2011-12-15 한국과학기술연구원 단백질 키나아제 저해활성을 가지는 2,4,7-치환된 티에노[3,2-d]피리미딘 화합물
WO2012004900A1 (en) 2010-07-09 2012-01-12 Aska Pharmaceutical Co., Ltd. Thienopyrimidine compounds
FR2988722B1 (fr) 2012-04-03 2014-05-09 Sanofi Sa Nouveaux derives de thienopyrimidines, leurs procedes de preparation et leurs utilisations therapeutiques

Also Published As

Publication number Publication date
PL2834248T3 (pl) 2016-09-30
US20200078370A1 (en) 2020-03-12
US10980816B2 (en) 2021-04-20
US20170319594A1 (en) 2017-11-09
HK1248214A1 (zh) 2018-10-12
IL234960A (en) 2017-06-29
UA112685C2 (uk) 2016-10-10
US10736904B2 (en) 2020-08-11
CN107652303B (zh) 2020-08-04
AR090572A1 (es) 2014-11-19
MA37384A1 (fr) 2016-06-30
EP2834248A1 (en) 2015-02-11
US20190151330A1 (en) 2019-05-23
US9115140B2 (en) 2015-08-25
EA201491820A1 (ru) 2015-02-27
HUE027895T2 (en) 2016-10-28
ES2577382T3 (es) 2016-07-14
MA37384B1 (fr) 2017-03-31
SG11201406091RA (en) 2014-10-30
CR20140435A (es) 2015-03-13
AU2013244992A1 (en) 2014-10-23
US20150352124A1 (en) 2015-12-10
CO7091179A2 (es) 2014-10-21
HK1201263A1 (zh) 2015-08-28
CA2868685C (en) 2021-01-12
FR2988722A1 (fr) 2013-10-04
TWI579288B (zh) 2017-04-21
EA025558B1 (ru) 2017-01-30
CL2014002661A1 (es) 2014-12-26
JP2015512434A (ja) 2015-04-27
AU2013244992B2 (en) 2017-04-20
SI2834248T1 (sl) 2016-07-29
KR20150001781A (ko) 2015-01-06
UY34725A (es) 2013-09-30
DK2834248T3 (en) 2016-07-04
ZA201407021B (en) 2015-11-25
PT2834248E (pt) 2016-06-24
US10500212B2 (en) 2019-12-10
KR102039764B1 (ko) 2019-11-01
CN104540834A (zh) 2015-04-22
MY166151A (en) 2018-06-06
CN107652303A (zh) 2018-02-02
PH12014502180B1 (en) 2014-12-10
CA2868685A1 (en) 2013-10-10
TW201345914A (zh) 2013-11-16
CN104540834B (zh) 2017-11-14
US20130261106A1 (en) 2013-10-03
JP6096278B2 (ja) 2017-03-15
US20200323874A1 (en) 2020-10-15
US9744176B2 (en) 2017-08-29
EP2834248B1 (en) 2016-03-16
MX355104B (es) 2018-04-05
HRP20160649T1 (hr) 2016-07-15
DOP2014000216A (es) 2017-09-15
CY1117843T1 (el) 2017-05-17
TN2014000415A1 (en) 2015-12-21
BR112014024489B1 (pt) 2020-11-10
WO2013150036A1 (en) 2013-10-10
RS54850B1 (sr) 2016-10-31
PH12014502180A1 (en) 2014-12-10
US10220044B2 (en) 2019-03-05
FR2988722B1 (fr) 2014-05-09
PE20150289A1 (es) 2015-03-05

Similar Documents

Publication Publication Date Title
TN2014000415A1 (en) Novel thienopyrimidine derivatives, processes for the preparation thereof and therapeutic uses thereof
AU2012324803A8 (en) (hetero)aryl cyclopropylamine compounds as LSD1 inhibitors
IN2014MN02496A (es)
MY164776A (en) Heterocyclic compound
MX352928B (es) Compuestos de piridazina-amida.
EA201491149A1 (ru) Пиразолопиридиновые производные, способы их получения и их терапевтическое применение
MX2013015308A (es) Inhibidores de proteasoma y procesos para su preparacion, purificacion y uso.
IN2014DN07509A (es)
GEP201706690B (en) Novel process for making compounds for use in treatment of cancer
MX351863B (es) Compuesto de anillo fusionado quinolilpirrolopirimidilo o sal del mismo.
MX349548B (es) Compuestos de tienopirimidina.
MX2014002832A (es) Nuevas imidazol-aminas como moduladores de la actividad de cinasas.
JO3196B1 (ar) عملية تحضير ملح ل – ارجينين البيريندوبريل
MX364400B (es) Compuestos de tetraciclina.
JO3063B1 (ar) مركب مبتكر وطرق لانتاجه
IN2014DN00144A (es)
GEP201706655B (en) Deuterated 1-piperazino-3-phenyl indanes for treatment of schizophrenia
WO2012140490A3 (en) Processes for preparing pitavastatin calcium
WO2014087208A3 (en) A process of preparing alcaftadine
AU2013237020A8 (en) Sulphonamide derivatives of benzylamine for the treatment of CNS diseases
TN2015000095A1 (en) Macrolide derivatives, preparation thereof and therapeutic use thereof
MX2015002705A (es) Compuestos de piridinona para usarse en terapia fotodinamica.
MX348841B (es) Derivados de pirimidooxazocina como inhibidores de mtor.
MX2013006670A (es) Derivado de 2-carboxamida-4-piperazinil-benzofurano.
EA033160B1 (ru) Соединения для лечения заболеваний, связанных с ишемией-реперфузией

Legal Events

Date Code Title Description
FG Grant or registration